---
slug: tirzepatide-glp1-agonists
title: "tirzepatide glp1 agonists"
kind: standard
status: published
hash: cc205d147ba4417ec5e972bbbe2b1339e9921f4ede134b79c2aeb39a457a317c
created: 2026-06-29T17:45:36.023Z
updated: 2026-10-08T11:49:30.728Z
summary: "Evidence is being populated by Grok web"
tags: []
above: []
below: []
adjacent: []
nested: []
---
# tirzepatide glp1 agonists

*Evidence is being populated by Grok web*

## Overview
Evidence is being populated by Grok web search.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-06-29T17:45:54.298Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration](https://pubmed.ncbi.nlm.nih.gov/40746703/) — “A dose-dependent tirzepatide was superior to placebo and GLP-1 RAs in weight reduction. However, the lean mass reduction and tolerability require further investigation.” (sha256 72db5087da8d14da)
2. [Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial](https://pubmed.ncbi.nlm.nih.gov/42119587/) — “We evaluated the efficacy and safety of continuing tirzepatide at the maximum tolerated dose (MTD) or lowering the dose to 5 mg compared with placebo.” (sha256 c25f8fac32fb17d0)
3. [Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes](https://clinicaltrials.gov/study/NCT06820281) — “This mechanistic study will define mechanisms by which GLP1-GIP co-agonism may uniquely provide clinical benefits in T1D during the fasting and fed states.” (sha256 7481a04538375a8c)
4. [Tirzepatide as Compared with Semaglutide for the Treatment of Obesity](https://pubmed.ncbi.nlm.nih.gov/40353578/) — “Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight.” (sha256 63e1eed5a123b6cf)
5. [Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Clinical Trial](https://pubmed.ncbi.nlm.nih.gov/41264593/) — “Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.” (sha256 8384b1e0c2332883)
6. [Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41761267/) — “These findings suggest that tirzepatide provides cardiovascular benefit at least comparable to established GLP-1RAs, supporting its emerging role in cardiovascular risk reduction in T2D.” (sha256 c71a8969e3a72eac)
7. [Causes and consequences of discontinuation of GLP1RAs and tirzepatide](https://pubmed.ncbi.nlm.nih.gov/42168641/) — “In this Review, we discuss common reasons for GLP1R agonist and tirzepatide discontinuation and examine available evidence related to potential cardiometabolic ...” (sha256 1cd36cc8c8fd9bb6)
8. [Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists](https://pubmed.ncbi.nlm.nih.gov/41655764/) — “Among patients with T2D taking a GLP-1 RA, tirzepatide was associated with lower risks of retinal complications, need for vision-saving ...” (sha256 e2267988b0881dee)
9. [Weight Loss With GLP-1 Agonists in Nondiabetic Adults](https://pubmed.ncbi.nlm.nih.gov/41936548/) — “Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes.” (sha256 71633aad767378b7)